Bronchodilator reversibility in patients with asthma and persistent airflow limitation - Authors' reply
- PMID: 36332641
- DOI: 10.1016/S2213-2600(22)00366-6
Bronchodilator reversibility in patients with asthma and persistent airflow limitation - Authors' reply
Conflict of interest statement
HAMK reports grants from Chiesi Farmaceutici, GlaxoSmithKline, and Novartis; and consulting fees paid to their institution from GlaxoSmithKline and Novartis. MvdB reports research grants paid to their institution from GlaxoSmithKline, Chiesi Farmaceutici, AstraZeneca, Novartis, Genentech, and Roche. TMK declares no competing interests.
Comment on
-
Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study.Lancet Respir Med. 2023 Jan;11(1):55-64. doi: 10.1016/S2213-2600(22)00185-0. Epub 2022 Jul 27. Lancet Respir Med. 2023. PMID: 35907424
-
Bronchodilator reversibility in patients with asthma and persistent airflow limitation.Lancet Respir Med. 2022 Nov;10(11):e94-e95. doi: 10.1016/S2213-2600(22)00363-0. Lancet Respir Med. 2022. PMID: 36332640 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical